Reaffirming guidance, especially when it aligns with analyst expectations, is generally viewed positively by the market as it indicates management's confidence in the company's financial health and future performance. For Modivcare, maintaining its revenue and adjusted EBITDA guidance for FY24 suggests stability and potential growth, likely leading to a positive short-term impact on its stock price.